ABSTRACT
The drug discovery process requires introduction of new paradigms that would qualitatively change development of new therapeutics. A critical part of the drug discovery process is to evaluate the therapeutic potential of putative drugs in relevant animal models of cancer. The combination of optical imaging with hollow fibers not only allows rapid, repetitive, and longitudinal evaluation of anticancer drugs in animals but also enables to evaluate molecular pathways in vivo. A big challenge in drug discovery is to expedite in vivo evaluation of in vitro leads, that is, to investigate whether a compound capable of acting on a target in vitro will also hit the target in vivo. Drug administration on day 56 and day 59 had no immediate effect on either bioluminescence or the size of the tumor. One approach in facilitating the use of genetically engineered mouse in drug development while retaining a significant throughput screening is to use exogenous fluorescent probes.
